Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Thursday, September 3, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Stoke Therapeutics and Biogen presented long-term clinical data on zorevunersen at the 16th European Epilepsy Congress. The Phase 1/2a open-label extension studies demonstrated significant and sustained reductions in seizures, alongside improvements in cognitive and behavioral outcomes for patients receiving the investigational treatment in conjunction with standard anti-seizure medications.
Market Sentiment Analysis
POSITIVE FACTORS
Substantial and durable reductions in seizures observed.
Improvements in cognition and behavior reported.
Long-term data supports disease-modifying potential.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis
Full Press Release Details
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines – – New data showed substantial
Frequently Asked Questions
What is zorevunersen?
Zorevunersen is an investigational medicine aimed at treating Dravet syndrome.
What were the key findings presented at EEC?
The findings highlighted significant reductions in seizures and improvements in cognition.
What type of study was conducted for zorevunersen?
A Phase 1/2a open-label extension study was conducted to evaluate its effects.
How does zorevunersen work with standard treatments?
Zorevunersen is used alongside standard anti-seizure medications for enhanced efficacy.